BRIEF published on 10/08/2026 at 08:35, 1 month 6 days ago GenSight Biologics and National Hospital Publish GS030 Trial Outcomes Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa GS030 PIONEER Trial
BRIEF published on 10/08/2026 at 08:35, 1 month 6 days ago Publication of the results of the GS030 trial for retinitis pigmentosa Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa Trial Results
PRESS RELEASE published on 10/08/2026 at 08:30, 1 month 6 days ago Inside Information / Other news releases GenSight Biologics and 15-20 National Hospital publish NEJM article on GS030 Phase 1/2 trial results for retinitis pigmentosa treatment, showcasing promising optogenetics approach GenSight Biologics Optogenetics 15-20 National Hospital NEJM Article GS030
BRIEF published on 10/08/2026 at 07:05, 1 month 6 days ago GenSight Biologics Secures €1 Million Funding from Shareholders Shareholders Fundraising Financial Strategy GenSight Biologics Retinal Therapies
PRESS RELEASE published on 10/08/2026 at 07:00, 1 month 6 days ago Inside Information / Other news releases GenSight Biologics successfully completes €1.0 million fundraising subscribed by existing shareholders. Proceeds to be used for operational activities and working capital requirements Shareholders Working Capital Fundraising Operational Activities GenSight Biologics
BRIEF published on 10/08/2026 at 01:06, 1 month 6 days ago Financial position of GenSight Biologics as of September 30, 2026 Treasury Bridge Financing GenSight Biologics Phase III RECOVER Access Programs
BRIEF published on 09/30/2026 at 00:42, 1 month 14 days ago GenSight Biologics Reports 2026 Interim Financial Results Funding Challenges GenSight Biologics Early Access Programs Financial Results 2026 Clinical Trials Update
PRESS RELEASE published on 09/30/2026 at 00:37, 1 month 14 days ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2026, including revenue of €(1.2) million, highlighting successful manufacturing technology transfer and progress in clinical studies Revenue Clinical Studies GenSight Biologics Interim Financial Results Manufacturing Technology Transfer
BRIEF published on 09/08/2026 at 07:35, 2 months 6 days ago GenSight Biologics: Review and Outlook as of September 2026 GenSight Biologics Gene Therapies REVISED STUDY LUMEVOQ® Manufacturing Access Programs
PRESS RELEASE published on 09/08/2026 at 07:30, 2 months 6 days ago Inside Information / Other news releases GenSight Biologics provides business updates on manufacturing, clinical activities, and financial status for September 2026, including progress on gene therapy treatments Financial Updates Manufacturing Business Updates Clinical Activities GenSight Biologics
Published on 11/14/2026 at 12:56, 2 hours 13 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 13 hours 39 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 14 hours 29 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 14 hours 34 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 15 hours 9 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 15 hours 45 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 17 hours 17 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 20 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 18:04, 21 hours 5 minutes ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 1 day 3 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/12/2026 at 23:12, 1 day 15 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 18:36, 1 day 20 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 1 day 21 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 1 day 21 hours ago Financial information for the period ended 30 September 2026
